Dr. Wolfgang Rehmann

Wolfgang is one of the leading experts on pharmaceutical law and medical device law in Germany. With his many years of industry knowledge and international experience, he represents small and medium-sized companies from the pharmaceutical and medical device industries, as well as global players.

In the Life Sciences team of Taylor Wessing, Wolfgang develops solutions for complex, strategic challenges facing this sector. In addition, he represents his clients' interests before authorities and in court, including in European court proceedings in Luxembourg. Wolfgang is also a lecturer at the University of Marburg.

CV

Since 1987 Partner, Taylor Wessing

1983 – 1987 Associate, Zimmermann Hohelohe Sommer Rojahn

1982 – 1983 In-house Counsel, Fraunhofer Gesellschaft

Career

Since 1987 Partner, Taylor Wessing

1983 – 1987 Associate, Zimmermann Hohelohe Sommer Rojahn

1982 – 1983 In-house Counsel, Fraunhofer Gesellschaft

Education

1983 Admitted as a lawyer, Munich

1983 Doctoral degree, Dr. iur. utr., Ludwig-Maximilians-Universität of Würzburg

1982 Second state examination, Bayern

Publications

Kommentar zur Verordnung über Medizinprodukte; Co-Author: Dr. Susanne A. Wagner; Beck Verlag; 2023

AMG Kommentar Beck Verlag

MPG Kommentar co-author Beck Verlag

Arzthaftungsprozess, Luchterhand co-author

Arzneimittel und Recht, regular publications

PharmaRecht, regular publications

Medzinprodukte Journal, regular publications

Medizinproduktrecht, regular publications

Memberships & Associations

GRUR
LIDC

Additional languages

Awards

Lexology Index 2025

Featured

Lexology Index 2025

The Best Lawyers™ in Germany 2025

Chambers Germany 2025

Experience

Pharmaceutical portfolio divestments across 24 EU jurisdictions

Teva Pharmaceuticals Europe BV on its divestments of portfolios of generic pharmaceutical products (approximately 260 medicinal products) in 24 EU jurisdictions to multiple purchasers, in addition to advising Teva on the divestment of certain parts of its business. The divestments were a condition enforced by the European Commission to approve Teva's USD40.5 billion acquisition of Allergan plc’s global generics and have been run as a competitive auction process, resulting in five asset sales.

Evelyne Friedel

Dr. Wolfgang Rehmann

Radovan Pala, Ph.D., LL.M.

Provision of pan-European pharma and patent advice

A leading international healthcare company on provision of European-wide advice across a variety of legal areas including pharmaceutical law and patents.

Dr. Wim Maas

Dr. Wolfgang Rehmann